Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of Pancreatic
FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.
Recent PostsSee All
Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and CEO of Nammi Therapeutics, and highlighted the most recent achie
Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in Southern California. Nammi Therapeutics will receive one year
The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the development of a safer, more tolerable alternative. The CIRM Board award